This content is machine translated Lymphoma Treatment goal: slow progression, improve quality of life Cancers of the lymphatic system affect around 1750 people in Switzerland every year. Intensive research has led to treatment becoming significantly more effective and tolerable in recent years. Even if…
View Post 10 min This content is machine translated "Watch and wait," radiation or systemic therapy? Diagnosis and treatment options for “indolent” non-Hodgkin’s lymphoma. The term indolent lymphomas encompasses a growing number of low-malignant non-Hodgkin lymphomas and leukemias predominantly of the B-cell series. They are differentiated and classified from each other based on their…
View Post 3 min This content is machine translated Non-Hodgkin's Lymphoma Pomalidomide in high-risk patients. Because data on the efficacy of pomalidomide in high-risk relapsed/refractory multiple myeloma populations are sparse, a phase II study set out to evaluate the agent in patients with GEP70 or…
View Post 6 min This content is machine translated Nodal lymphoma from the pathology point of view Update for daily practice A persistent lymphadenopathy is a clear indication for further histopathological diagnosis. A detailed medical history as well as knowledge of previous diseases, manipulations and drug therapies are essential for a…
View Post 6 min This content is machine translated Non-Hodgkin's lymphoma and myelodysplastic syndrome What are the benefits of lenalidomide and pomalidomide? At the ASH Congress in New Orleans, the focus was on the efficacy and safety of lenalidomide plus low-dose dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.…
View Post 6 min This content is machine translated Chronic lymphocytic leukemia and non-Hodgkin's lymphoma Updates on the active ingredients GA101 and rituximab Three studies on chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma were discussed at the ASH in New Orleans: One was an update on the stage 1 analysis of the CLL11…
View Post 5 min This content is machine translated Non-Hodgkin's Lymphoma “The new drugs will fundamentally change the therapeutic landscape” In an interview with InFo ONCOLOGY & HEMATOLOGY, Prof. Christoph Driessen, MD, Head Physician of the Department of Oncology/Hematology at the Cantonal Hospital St. Gallen, provides information on the pathogenesis,…
